The Cardio-Metabolic Clinic

Inclusion: * \>18 years * Capable of giving written informed consent * Established diagnosis of T2D * Having established heart or vascular disease defined as either: * Atherosclerotic disease defined as: 1. Prior acute coronary syndrome (ACS). 2. Chronic coronary syndrome defined as the combination of: Angina pectoris AND coronary atherosclerosis assessed with either Coronary CT angiography (CTA) or Myocardial-scintigraphy (MPI) or Coronary angiography (CAG) AND treatment with statins and/or acetylsalicylic acid. 3. Stroke. 4. Peripheral arterial disease (PAD) defined as: Claudication intermittence in combination with pathological ABI AND/OR vascular PAD surgery AND/OR ischemic amputation. 5. Ischemic heart disease defined by one of the following criteria: a) Myocardial-scintigraphy: \>10% reversibility OR b) Coronary CT angiography: Coronary Artery Calcium (CAC)-score \>100. * Heart failure (HF): HF with reduced ejection fraction (HFrEF), HF with Mildly reduced ejection fraction (HFmrEF), HF with preserved ejection fraction (HFpEF) * Atrial fibrillation and/or flutter, including paroxysmal, persistent and chronic disease * Valvular heart disease (which requires control in outpatient clinic of cardiology), such as aortic valve stenosis, mitral valve insufficiency, and patients with aortic dilatation * Hypertension treated with at least three antihypertensive drugs Exclusion: * Life expectancy less than 5 years for any reason * Type 1 Diabetes Mellitus * Participation in another clinical trial with an investigational product or device that could interfere with the primary and/or secondary endpoints of this study